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Abstract
Although the mechanism of dry eye disease is not clearly understood, it is certain that inflammation and the
immune response play a major role in determining the health of the ocular surface in dry eye patients. Accurate ocular
surface characterization during the early stages of dry eye disease is critical for successful treatment, because
there exists no single standard, objective test to diagnose the early phase of dry eye disease. The treatment
target should be direct to prevent the perpetuation of chronic inflammation and immune responses. Numerous
studies have categorized dry eye disease as an autoimmune-related inflammatory disease. However, relatively little is
known about how innate immune mechanisms act following a local insult, why some patients are particularly
vulnerable, and why local inflammation fails to resolve in these patients. Within this review, particular attention
will be given to the very early events and corresponding defense mechanism in dry eye disease. The transition
from innate to adaptive immunity will also be discussed.
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Background
The tear film, lacrimal glands, corneal and conjunc-
tival epithelia, and meibomian glands constitute a lac-
rimal function unit (LFU) that serves to preserve the
health of the ocular surface. The components of the
LFU work together to maintain homeostasis despite
internal and external insults [1, 2]. Dry eye disease
(DED) is a highly prevalent inflammatory disease of
the LFU that is multifactorial in nature. The defin-
ition of DED has evolved from mere tear deficiency
to chronic inflammation and the resultant immuno-
logic responses [3, 4]. Whether the inflammation is a
cause or result of DED remains to be elucidated. The
mechanisms explaining how and when homeostasis is
disrupted following local insult or inflammation of
the ocular surface are unclear.
The immune reaction comprises innate and adapted
immunity, which differ vastly in terms of methodology
as well as objective. Recent research has examined how
the innate immune system influences adaptive immune
responses [5]. Understanding the interface between
innate and adaptive immunity would help to define
the factors that trigger the adaptive immune response
and allow for analysis of autoimmune and allergic dis-
eases from a new perspective. Although the immuno-
pathologic events that sustain the systemic adaptive
immune response in DED have been characterized,
the stressor that triggers the innate immune response
and the interface between innate and adaptive im-
mune mechanisms are not well defined. If the compli-
cated crosstalk between innate sensory function and
the adaptive response at the ocular surface could be
understood, the pathogenesis of DED would be clearer.
We aimed to briefly review the clues of innate immunity
and the interface between innate and adaptive immunity
in DED.
Innate immunity
In DED, a chronic inflammatory reaction is generated
at the ocular surface, accompanied by the destruction
of epithelial tight junctions and finally sloughing of
the surface epithelia [6]. The epithelium is part of the
innate immune response, playing a crucial role in pre-
venting the invasion of ocular tissue by foreign bodies
or microorganisms [7]. Eyelid blinking, the barrier
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posed by the epithelium, secretory proteins such as
lysozyme, and conjunctival mucous are additional as-
pects of the innate immune response at the ocular
surface [8].
Corneal and conjunctival epithelial and epithelial-
associated Langerhans cells are known to express a
range of both toll-like receptors (TLR) and NOD-like
receptors (NLR). The TLR and NLR pathways are the
primary route by which host cells detect the presence
of foreign invaders. The responses triggered include
the production of cytokines, chemokines, and anti-
microbial peptides. Increasing the expression of TLR
or NLR may prevent the risk of infection but may
also lead to inflammation. There is some evidence
that TLR expression is modulated at the ocular sur-
face in DED. In an experimental DED model, TLR2-4
and TLR9 expression was increased at the ocular sur-
face and lacrimal glands [9, 10].
The rate of epithelial turnover is increased in DED,
with viable corneal surface cells shed by classical apotosis
[11, 12]. Dead cells can release endogenous extracellular
DNA (eDNA), a type of damage-associated molecular
pattern (DAMP) that activates innate immunity [13].
Sonawane et al. found that eDNA and neutrophils were
present on the ocular surface in DED patients and sug-
gested that eDNA production and clearance mechanisms
are dysregulated in DED [14]. The authors suggested that
accumulated eDNA and neutrophil extracellular trap
(NET) in the pre-corneal tear film would result in the in-
flammation characteristic of DED.
Lactoferrin, which is secreted by acinar cells of the
lacrimal glands, has anti-inflammatory, anti-cancer, and
immune-modulating properties. Lysozyme, another
secretory protein from acinar cells in the main lacrimal
gland and conjunctival accessory lacrimal glands, at-
tacks the cell walls of bacteria. The levels of lactoferrin
and lysozyme are reported to be decreased in the tear
fluid of DED patients [15, 16]. The level of secretory
IgA (sIgA), a key factor that protects against microbes
in the mucosa, is decreased in DED patients [16]. Thus,
decreased sIgA levels inhibit proper modulation of the
ocular surface flora, which in turn increases the risk of
microbial infection. The expression of secretory phospho-
lipase A2 (sPLA2) is increased in the tears of DED patients,
which suggests that sPLA2 plays a major role in preventing
microbial infection at the ocular surface in DED patients
[17]. The altered expression of molecules involved in the
innate immune response in dry eye may have other effects
on the innate immune system as well as trigger an adaptive
response if not properly managed.
Mucins keep the ocular surface moist and protect it
from external stimuli, and the induction of mucin
from the ocular surface may facilitate the stability of
the tear film [18]. Mucins are high-molecular weight
glycoproteins characterized by their extensive O-
glycosylation [19]. Major mucins expressed by the
ocular surface epithelia include cell surface-associated
mucins MUC1, MUC4, MUC16, and the gel-forming
mucin MUC5AC. Recent advances using functional
assays have allowed the examination of their roles in
the protection of corneal and conjunctival epithelia.
Among these, MUC1 genotype polymorphism has
been shown in DED [20]. Differences in MUC1 geno-
types between healthy controls and DED patients
could explain the loss of ocular surface integrity. The
loss of mucins at the ocular surface may result in an
increased risk of infection and epithelial stress, which
could trigger the adaptive immune response.
Very recently, Desiccating stress-induced chemokine
expression in the epithelium was shown to be dependent
on upregulation of NKG2D/RAE-1 and release of IFN-γ
in experimental DED [21]. Upregulation of CXCL9,
CXCL10, and CXCL11 expression was notedto be T
cell–independent, requiring IFN-γ–producing NKG2D+
NK cells that are activated in response to DS-induced
stress signals. This suggest that the triggering immune
response in DED pathology.
Triggering adaptive immune response
Environmental triggers may also contribute to the ini-
tiation and perpetuation of the disease. The activation
of innate immunity results in antigen presentation, T-
cell activation, and the release of pro-inflammatory
cytokines [22]. These changes activate the adaptive
immune system and auto-antibodies. No known anti-
bodies are known to be involved in DED; however,
there is mounting evidence that DED is a localized
self-antigen–driven autoimmune-based inflammatory
disease [4].
Immune-mediated inflammatory disease (IMID) is
associated with various conditions. While the exact
etiology is undefined, both genetic and environmental
factors play an important role in its pathogenesis.
Recently, genome-wide association studies (GWASs)
using millions of nucleotide polymorphisms as gen-
omic markers and non-synonymous single nucleotide
polymorphisms (nsSNP) have identified loci involved
in IMID susceptibility [23]. Murakami et al. also re-
ported that IL1B polymorphisms (genotypes CC, TT,
and AA in positions -511, -31, and 3877, respectively)
were significantly less frequent in Sjogren’s syndrome
patients than controls or patients with SLE [24]. We
identified certain genetic variations by screening for
pro-inflammatory cytokine genes in Korean non-
Sjogren’s DED patients. Among the screened genes,
rs1143634 of interleukin-1 beta (IL1B) and rs8192284
of interleukin-6 receptor (IL6R) were linked to sus-
ceptibility among Korean non-Sjogren’s DED patients
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[25]. IL1B is a pro-inflammatory cytokine that is
considered to be important in the pathogenesis of
DED [26]. We also observed that the genotypic and
allelic distributions of rs8192284 in the IL6R gene
differed between DED patients and controls. The
exact role of IL6 is unclear, and both its pro- and
anti-inflammatory properties require further investi-
gation. The balance between pro- and anti-inflammatory
effects of IL6 was previously suggested to favor pro-
inflammatory molecules under various environmental
conditions [27].
The inflammatory response can resolve insults to the
tissue and restore homeostasis [5]. However, inappro-
priate control of the natural defense mechanism results
in chronic inflammation and disease progression. The
resolution of inflammation is critical to the transition
from innate to adaptive immunity [5, 28]. The inflamma-
tory IL6 and soluble IL6 receptors are known to direct
the transition from innate to adaptive immunity [28].
Traditionally, IL6 was regarded as an activator of acute-
phase responses; recent findings have shown a series of
IL6-mediated events are critical for resolving the innate
immune response [29]. Levels of IL6, which may con-
tribute to DED pathogenesis, are reported to be in-
creased in the tears and conjunctival epithelium of DED
patients [30]. The expression of soluble IL6 receptor
(sIL-6R) in tears is upregulated in chronic inflammatory
conditions affecting the ocular surface [31, 32]. Previ-
ously, we demonstrated that the levels of IL-1B, IL-6
and their soluble receptors sIL-1R1 and sIL-6R were
significantly elevated in the tears of patients with
DED [33]. We assumed that the IL-6/sIL-6R complex
mediates the pathogenesis of DED and that the
marked elevation of its natural antagonist, soluble
glycoprotein 130 (Sgp130), may act to preserve ocular
homeostasis in response to local inflammation. Inter-
estingly, we also demonstrated decreased levels of IL-17A
and interferon gamma (INF-r) in the tears of DED pa-
tients. We interpreted the results as evidence that the
suppressor T-cell, which is a natural inhibitor of self-
reactive Th1 (INF-r), Th2 (IL4+), and Th17(IL17A)
cells, may function to some extent in the mild and early
stages of DED [34]. In the clinical setting, it is rare to
see advanced DED unaccompanied by systemic auto-
immune disease. Moreover, patching the eyelid to protect
against external stimuli and supplying artificial tears
without any anti-inflammatory agent can resolve the
symptoms and signs of mild DED. This phenomenon
suggests that normal tissue architecture is preserved
despite local insult and inflammation. However, when
some mediators such as sIL-6 act negatively, various
cytokines and chemokines act on both arms of the
immunologic response. The interface between the in-
nate and adaptive immune responses, and triggering
factors initiating adaptive immune responses in DED
remains to be elucidated by future clinical trials and
research approaches.
Discussion
This review presents the current evidences for the
role of innate immunity and an interface between in-
nate and adaptive immunity in early DED (Table 1).
Although the triggering factors remain unclear, there
is evidence that changes in the defense mechanism at
the ocular surface and genetic factors contribute to
the pathogenesis of LFU disruption and inflammation
in DED (Fig. 1). Environmental, microbial and en-
dogenous stressors, antigen localization, and genetic
factors may provide the trigger for an acute inflamma-
tory event that initiates the vicious cycle of chronic in-
flammatory DED [35].
Disruptions to the primary ocular barrier (innate
immunity) in DED would be expected to allow for
pathogen invasion. However, there has been little evi-
dence published to connect microbial keratitis and
DED. This may imply that DED patients have stronger
innate immunity to ocular surface damage and infec-
tion. It is also possible that changes in the expression
of TLRs, innate immune molecules (secretory pro-
teins), and mucins in DED may represent a compro-
mised innate immune response. Failure of the innate
response could trigger an adaptive immune response.
Clinical and basic science research to accurately evalu-
ate innate and adaptive immunity in DED are neces-
sary because none of the hypothesis itself only (innate,
adaptive immunity) can definite in the pathogenesis of
DED. The diagnosis of DED, especially in its early
stages, has been hampered in clinical settings. Future
research should focus on techniques to detect the
early signs (innate immunity) in DED patients, and to
facilitate the resolution of local inflammation at the
ocular surface in order to prevent progression to
chronic disease (adaptive immunity). To date, western
DED researchers (United States, Europe) have focused
on inflammation and the immune response, while
Asian researchers (Japan, Korea) have focused on the
corneal epithelium.
Table 1 Factors associated with innate immunity and triggering
into adaptive immunity
Innate defences blinking, tear film, epithelium, secretory proteins,
mucin, Langerhans cell, extracellular DNA, neutophil
extracellular trap
Trigger T-cell activation, proinflammatory cytokines, genetic
polymorphisms, inappropriate control of acute
inflammation, homeostasis break
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Conclusion
Within this review, we discussed the early events and
defense mechanism of DED. The current knowledge
might be the tip of an iceberg and further studies relating
pathogenesis must be sought. By understanding the mech-
anisms of early event of immune dysfunction through
basic science and translational research, potential drug
targets can be identified.
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